Results 121 to 130 of about 5,159 (158)

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.   +8 more
europepmc   +1 more source

Lipid-lowering therapy: Evidence and future perspective. [PDF]

JRSM Cardiovasc Dis
Komiyama M, Wada H, Dan GA, Hasegawa K.
europepmc   +1 more source

Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial. [PDF]

Front Cardiovasc Med
Kim W, Park S, Shin JH, Kook H, Lim YH.
europepmc   +1 more source

Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia. [PDF]

J Clin Med
Khattak S, Ochoa-Ferraro A, Khan N, George S, Khan SQ, Townend JN, Dawson C, Thomas MR.   +7 more
europepmc   +1 more source

Severe angioedema requiring airway intervention following evolocumab administration: a case report. [PDF]

Am J Cardiovasc Dis
Mojahedi A, Friedman A, Idries I, Farid M, Ghannam M, Chadow H.   +5 more
europepmc   +1 more source

The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction. [PDF]

PLoS One
Li H, Dong H, Bao S, Wang X, Fu Z.
europepmc   +1 more source

Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial. [PDF]

Sci Rep
Jing A, Wang J, Zhang M, Liang Y, Liu J, Zhang N, Wang J, Li X, Li C, Cui Z, Liu Y, Gao J.   +11 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]

Front Pharmacol
Hu D, Deng X, Feng M, Zhang X, He Q, Wang T, Feng Z.   +6 more
europepmc   +1 more source